Geneva (Switzerland), April 18, 2017 : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today the initiat ...
Geneva (Switzerland), March 28, 2017 : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosi ...
Lyon, France – 21 March 2017 – NETRIS Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors. NETRIS Pharma, a pioneer in the development of dependence receptor target ...
February 28, 2017 Genticel's General Meeting approves the strategic Combination with GenKyoTex SA Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunother ...
Geneva (Switzerland), 7 February 2017 : (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), ...
Toulouse and Geneva, December 22, 2016 Genticel and Genkyotex Announce Intention to Enter into Strategic Combination. Genkyotex is a pioneer in discovery and development of NOX therapeutics. Transaction would create ...
